A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients

NCT07052994 | Not Yet Recruiting Phase 1 DMC FDA Drug

• 2 other identifiers: 2024-1396NCI-2025-04739
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of Phase 1a of this clinical research study is to find the highest tolerable dose of revumenib that can be given in combination with cytarabine, daunorubicin, and gemtuzumab ozogamicin to patients who have acute leukemia. The goal of Phase 1b of this clinical research study is to learn if the dose of revumenib in combination with cytarabine, daunorubicin, and gemtuzumab ozogamicin found in Phase 1a can help to control the disease.

Conditions

Pediatric Acute Leukemia

Outcome Measures

Primary Outcomes (1)

• Safety and Adverse Events (AEs)

  Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

  Through study completion; an average of 1 year

Study Arms (2)

Dose Escalation of Revumenib in combination with cytrabine and Daunorubicin and GO

EXPERIMENTAL

Treatment will be administered on an inpatient basis

Drug: Revumenib; Drug: Cytrabine; Drug: Daunorubicin

Dose Expansion of Revumenib in combination with cytrabine and Daunorubicin and GO

EXPERIMENTAL

Treatment will be administered on an inpatient basis

Drug: Revumenib; Drug: Cytrabine; Drug: Daunorubicin

Interventions

Revumenib DRUG

Given by IV

Dose Escalation of Revumenib in combination with cytrabine and Daunorubicin and GO; Dose Expansion of Revumenib in combination with cytrabine and Daunorubicin and GO

Cytrabine DRUG

Given by IV

Dose Escalation of Revumenib in combination with cytrabine and Daunorubicin and GO; Dose Expansion of Revumenib in combination with cytrabine and Daunorubicin and GO

Daunorubicin DRUG

Given by IV

Dose Escalation of Revumenib in combination with cytrabine and Daunorubicin and GO; Dose Expansion of Revumenib in combination with cytrabine and Daunorubicin and GO

Eligibility Criteria

• Age: 6 Months - 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Age . 6 months - 21 years of age.
• ECOG performance status of \< 2.
• Phase 1a portion of the study: Relapsed/refractory AML, or MPAL per ELN/NCCN with a myeloid phenotype with KMT2Ar, NPM1c, NUP98r and UBTF-ITD.
• Phase 1b portion of the study: Frontline AML, or MPAL per ELN/NCCN with a myeloid phenotype with KMT2Ar, NUP98r and UBTF-ITD.
• WBC must be below 25,000/ ƒÊL at time of enrollment. Patients may receive cytoreduction prior to enrollment.
• Baseline ejection fraction must be \> 50%.
• Adequate hepatic function (direct bilirubin \< 2x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement, and AST and/or ALT \< 3x ULN unless considered due to leukemic involvement, in which case direct bilirubin or AST and/or ALT \< 5x ULN will be considered eligible).
• Potassium should be maintained at . 4.0 mEq/L and magnesium at \> 2.0 mg/dL. Maintenance PO supplementation should be started for patients who are below these thresholds, and Revumenib dosing instructions as provided in Table 2 should be followed.
• Adequate renal function (creatinine clearance .
• Willing and able to provide informed consent.
• The time between the previous treatment and the start of the new treatment will be at least 14 days for both cytotoxic and non-cytotoxic therapies, including immunotherapies, or it will be equivalent to 5 half-lives of the prior therapy, whichever is shorter.
• Oral hydroxyurea and/or cytarabine (up to 2 g/m2) for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the PI. Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted.
• Women of childbearing potential must agree to adequate methods of contraception during the study and at least 4 months (120 days) after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study and at least 4 months (120 days) after the last treatment.

You may not qualify if:

• Patients with any concurrent uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place the patient at unacceptable risk of study treatment.
• The use of other chemotherapeutic agents or anti-leukemic agents is not permitted during study with the following exceptions (1) intrathecal chemotherapy for prophylactic use or for controlled CNS leukemia. (2) use of hydroxyurea for patients with rapidly proliferative disease or for control of counts during differentiation syndrome. (3) use of steroids for treatment of differentiation syndrome.
• Patients with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications.
• Patients with a concurrent active malignancy under treatment.
• Known active hepatitis B (HBV) or Hepatitis C (HCV) infection or known HIV infection.
• Female subjects who are pregnant or breast-feeding.
• Patient has an active uncontrolled infection.
• Any of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (New York Heart Association Classification Class .II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident, or transient ischemic attack.
• QTc \>450 msec for males and QTc \>470 msec for females using the Fridericia Formula.
• History of or any concurrent condition, therapy, or laboratory abnormality that in the Investigator's opinion might confound the results of the study, interfere with the patient fs participation for the full duration of the study, or is not in the best interest of the patient to participate.
• Clinically active central nervous system (CNS) leukemia.
• Patients on immunosuppressive therapy post-HSCT at the time of screening with R/R leukemia (must be off all systemic immunosuppression therapy for at least 2 weeks and calcineurin inhibitors for at least 4 weeks). The use of topical steroids for cutaneous graft-versus-host disease (GVHD) or stable systemic steroid doses less than or equal to 0.2-0.3mg/kg of prednisone daily are permitted.
• Patients GVHD grade \>1 is not allowed.

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead

Study Sites (1)

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

• MD Anderson Cancer Center Website

MeSH Terms

Interventions

revumenib; Daunorubicin

Intervention Hierarchy (Ancestors)

Anthracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds; Aminoglycosides; Glycosides; Carbohydrates

Study Officials

• Branko Cuglievan, MD

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Branko Cuglievan, MD

CONTACT

(713) 563-1499; bcuglievan@mdanderson.org

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 30, 2025
• First Posted: July 8, 2025
• Study Start (Estimated): December 1, 2027
• Primary Completion (Estimated): December 31, 2032
• Study Completion (Estimated): December 31, 2034
• Last Updated: April 14, 2026

Record last verified: 2026-04

Locations

US (1)